NAFLD is the most common chronic liver condition in the United States. It's estimated that about 25 percent of adults in the U.S. have NAFLD. Of those with NAFLD, about 20 percent have NASH (5% of adults in the U.S.). 2022
https://t.co/veIKajGKQS #NASHawareness
#ASCO22 hasn't officially started yet and we are already at 18K mentions - 603 a day average. #Oncologists have a lot of good things to say. Who will be the #ASCO2022 Top Tweeter this year? I am the #DataWhisperer
Are you charging your #publications …with #social?
Join our plenary session on May 10 from 3:10-3:55pm EST at #ISMPPAnnual2022 to learn how to engage experts and amplify your publications. #HCG#MedComms
We are excited to attend #ISMPPAnnual2022 in Washington DC next week! Will you be attending?
Stop by our booth or send us a message via the #Whoova app to chat with our team!
#Publications#Medcomms
Update to #AACR22#MedTwitter activity. Looks like we will surpass the mentions from last year. Great conversations @AACR - both n person and in "the cloud" 🌤️
Interesting that slightly less users from last year, are generating 2x the reach of communication. #askmewhy
🚨Approval alert 👉🏼Huge news in #PrecisionMedicine 🎯👉🏼FDA approves alpelisib for PIK3CA-related overgrowth spectrum
✅Efficacy based on real-world data a + expanded access program for compassionate use in children+ adults @OncoAlert@tmprowell
https://t.co/zIni1VZNE4
You guessed it - #AACR22 is starting this week & TSG will be front and center to cover the event! Keep an eye out for some "Early Takes" on what we're looking forward to, and make sure to follow along for some additional "Hot Takes" following the congress #TSGcongresscoverage